Transcept will liquidate without deal to 'enhance' value
This article was originally published in Scrip
Executive Summary
Transcept Pharmaceuticals said on 4 December that if it cannot identify a transaction by the first quarter of 2014 to "enhance stockholder value" the company will liquidate its assets.